New combo aims to boost remission in Hard-to-Treat leukemia
NCT ID NCT05155709
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 30 times
Summary
This study tested a new drug called siremadlin added to two standard medicines (venetoclax and azacitidine) in adults with acute myeloid leukemia (AML) who are not healthy enough for strong chemotherapy. The goal was to see if the combination could improve response in patients who either did not respond well to initial treatment or had high-risk features at diagnosis. The study involved 14 participants and focused on safety and remission rates.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Novartis Investigative Site
Hong Kong, 999077, Hong Kong
-
Novartis Investigative Site
Budapest, H-1083, Hungary
-
Novartis Investigative Site
Beersheba, 8457108, Israel
-
Novartis Investigative Site
Jerusalem, 9112001, Israel
-
Novartis Investigative Site
Bologna, BO, 40138, Italy
-
Novartis Investigative Site
Alor Star, Kedah, 05460, Malaysia
-
Novartis Investigative Site
Kuala Selangor, 68000, Malaysia
-
Novartis Investigative Site
Izmir, Balcova, 35340, Turkey (Türkiye)
-
Oregon Health Sciences University
Portland, Oregon, 97239, United States
-
Texas Oncology Sammons Cancer Center
Dallas, Texas, 78246, United States
Conditions
Explore the condition pages connected to this study.